Clinical Trial Details
— Status: Completed
Administrative data
NCT number |
NCT05309564 |
Other study ID # |
BTX-Thailand |
Secondary ID |
|
Status |
Completed |
Phase |
N/A
|
First received |
|
Last updated |
|
Start date |
March 1, 2020 |
Est. completion date |
March 14, 2022 |
Study information
Verified date |
May 2023 |
Source |
Region Västerbotten |
Contact |
n/a |
Is FDA regulated |
No |
Health authority |
|
Study type |
Interventional
|
Clinical Trial Summary
This study aimed to evaluate the duration of a reduced maximal voluntary bite force after a
botulinum toxin intervention. Methods: In an intervention group, 25 units of Xeomin® (Merz
Pharma GmbH & Co KGaA, Frankfurt am Main, Germany) botulinum neurotoxin type A were injected
into the masseter muscles bilaterally (to a total of 50 units).
Description:
This study aimed to evaluate the duration of a reduced maximal voluntary bite force (MVBF)
after a botulinum toxin intervention. Methods: In an intervention group, 25 units of Xeomin®
(Merz Pharma GmbH & Co KGaA, Frankfurt am Main, Germany) botulinum neurotoxin type A were
injected into the masseter muscles bilaterally (to a total of 50 units). A control group did
not receive any intervention. MVBF was measured in Newtons using a strain gauge meter at the
incisors and first molars. The intervention group was comprised of individuals seeking
aesthetic treatment for masseter reduction (n = 20), and the control group (n = 12) comprised
of volunteers.